Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeikagakuTSE:4548 +0.81%72 ROC (Joel Greenblatt) % is 1.10% as of Mar. 2026, which is 86% below its 10-year median of 8.01. GuruFocus rates TSE:4548 with a GF Score™ of 72/100 and a GF Value™ of 円777.21 (Fairly Valued). The stock has 6 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Seikagaku ranks worse than 50.42% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Seikagaku's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.10%.
The historical rank and industry rank for Seikagaku's ROC (Joel Greenblatt) % or its related term are showing as below:
TSE:4548'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.91 Med: 8.01 Max: 27.13
Current: 4.13
During the past 13 years, Seikagaku's highest ROC (Joel Greenblatt) % was 27.13%. The lowest was -35.91%. And the median was 8.01%.
TSE:4548's ROC (Joel Greenblatt) % is ranked worse than 50.42% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.35
vs TSE:4548: 4.13
Seikagaku's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -27.90% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Seikagaku's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4548 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Seikagaku's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seikagaku ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Seikagaku's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 1.10% mean?
Seikagaku (TSE:4548) has a ROC (Joel Greenblatt) % of 1.10% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Seikagaku and its competitors. This is 86% below median its historical median of 8.01. According to the industry distribution chart, Seikagaku ranks #422 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is Seikagaku's ROC (Joel Greenblatt) % too high?
Seikagaku's current ROC (Joel Greenblatt) % of 1.10% is 86% below median its 10-year median of 8.01. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.35. Seikagaku's value of 1.10% is 74.7% below this industry median. Based on the distribution chart, Seikagaku ranks #422 out of 837 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Seikagaku has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seikagaku's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Seikagaku ranks #422 out of 837 companies for ROC (Joel Greenblatt) %. This places Seikagaku in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.35. Seikagaku's value of 1.10% is 74.7% below this benchmark. While the company's 10-year median is 8.01 vs. the industry median of 4.35, Seikagaku has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.35, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current ROC (Joel Greenblatt) % of 1.10% is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Seikagaku and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current ROC (Joel Greenblatt) % is 1.10%, which is 86% below median its own 10-year median of 8.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seikagaku stock overvalued right now?
Based on GuruFocus' analysis, Seikagaku (TSE:4548) is currently considered Fairly Valued. The stock's GF Value™ is 円777.21, compared to a current price of 円748.00 — trading 3.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 1.10%, which is 86% below median its 10-year median of 8.01 and 74.7% below the Medical Devices & Instruments industry median of 4.35. Seikagaku's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Seikagaku (TSE:4548), the current ROC (Joel Greenblatt) % is 1.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seikagaku (TSE:4548) Overvalued in 2026?
Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued.
The current stock price of 円748.00 is trading 3.8% below its estimated GF Value™ of 円777.21.
GuruFocus considers Seikagaku to be Fairly Valued.
Key valuation signals for TSE:4548:
ROC (Joel Greenblatt) %: 1.10% (86% below median its 10-year median of 8.01)
GF Value™: 円777.21 vs. price of 円748.00 (3.8% below fair value)
Industry Position: 74.7% below the Medical Devices & Instruments median (#422 of 837)
No single metric tells the full story. See the TSE:4548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
72GF Score
Get the complete analysis for TSE:4548
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4548 has been successfully added to your 
